Common medications can accumulate in gut bacteria, a new study has found, altering bacterial function and potentially reducing the effectiveness of the drug. These interactions – seen for a variety of medications, such as depression, […]
EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The […]
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) […]
Research from APC Microbiome Ireland (APC) at University College Cork (UCC) published in the leading international scientific journal Nature Aging introduces a novel approach to reverse aspects of aging-related deterioration in the brain and cognitive function […]
The number of published scientific papers on the microbiome has increased year after year for the past decade, and is now at an all-time high. Research is moving beyond preliminary association studies, toward more sophisticated […]
DayTwo, a leader in precision nutrition with the world’s most advanced proprietary microbiome science, today announced that the company appointed David Henderson, a former founding executive member of Oscar Health, as Chief Executive Officer. The […]
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The […]
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today it has entered into a definitive agreement with […]
A research team led by Dr Aixin YAN, Associate Professor from the Research Division for Molecular & Cell Biology, Faculty of Science, in collaboration with Honorary Clinical Professor Patrick CY WOO from the Department of […]
Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing […]
Microbiome research has accelerated rapidly in recent years—and while these studies have provided valuable insights into human health, they have also made clear that microbiome research alone will not answer all of our fundamental questions […]